PLoS By Category | Recent PLoS Articles

Biotechnology - Immunology - Molecular Biology - Pharmacology - Respiratory Medicine

PEI-Engineered Respirable Particles Delivering a Decoy Oligonucleotide to NF-?B: Inhibiting MUC2 Expression in LPS-Stimulated Airway Epithelial Cells
Published: Wednesday, October 03, 2012
Author: Francesca Ungaro et al.

by Francesca Ungaro, Daniela De Stefano, Concetta Giovino, Alessia Masuccio, Agnese Miro, Raffaella Sorrentino, Rosa Carnuccio, Fabiana Quaglia

A specific and promising approach to limit inflammation and mucin iperproduction in chronic lung diseases relies on specific inhibition of nuclear Factor-?B (NF-?B) by a decoy oligonucleotide (dec-ODN). To fulfill the requirements dictated by translation of dec-ODN therapy in humans, inhalable dry powders were designed on a rational basis to provide drug protection, sustained release and to optimize pharmacological response. To this end, large porous particles (LPP) for dec-ODN delivery made of a sustained release biomaterial (poly(lactic-co-glycolic) acid, PLGA) and an “adjuvant” hydrophilic polymer (polyethylenimine, PEI) were developed and their effects on LPS-stimulated human airway epithelial cells evaluated. The composite PLGA/PEI particles containing dec-ODN (i.e., LPPPEI) were successfully engineered for widespread deposition in the lung and prolonged release of intact dec-ODN in vitro. LPPPEI caused a prolonged inhibition of IL-8 and MUC2 expression in CF human bronchial epithelial cells and human epithelial pulmonary NCI-H292 cells, respectively, as compared to naked dec-ODN. Nonetheless, as compared to previously developed LPP, the presence of PEI was essential to construct a dec-ODN delivery system able to act in mucoepidermoid lung epithelial cells. In perspective, engineering LPP with PEI may become a key factor for tuning carrier properties, controlling lung inflammation and mucin production which, in turn, can foster in vivo translation of dec-ODN therapy.